SCHEMBL9890788

SCHEMBL9890788

Cc1ccc(CC(N)=O)c(-c2cccc(F)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICMT O60725 11/20 0.50
CHRM3 P20309 4/20 0.42
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ALOX15 P16050 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HPGD P15428 1/20 0.41
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
CASP1 P29466 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
KMT2A Q03164 1/20 0.40
RELA Q04206 1/20 0.40
SENP8 Q96LD8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890783 0.89 ICMT (0.50) ICMTCHRM3MAPTSMN1; SMN2ALOX15
SCHEMBL9890764 0.88 ICMT (0.54) ICMTSMN1; SMN2
SCHEMBL9890680 0.87 SRC (0.47) CHRM3MAPTSMN1; SMN2ALOX15NPSR1
SCHEMBL9890724 0.84 PTGDR2 (0.50) ICMTHPGDMEN1NPC1NFKB1
SCHEMBL26835272 0.83 ICMT (0.47) ICMTSMN1; SMN2HPGDNPC1RAB9A
SCHEMBL2392257 0.82 ICMT (0.54) ICMTPTGER2
SCHEMBL2395233 0.81 ICMT (0.53) ICMTCHRM3
SCHEMBL15832033 0.81 TAAR1 (0.49) CHRM3MAPTSMN1; SMN2ALOX15NPSR1
SCHEMBL9890774 0.80 ICMT (0.54) ICMT
SCHEMBL16520425 0.78 TAAR1 (0.50) CHRM3MAPTSMN1; SMN2ALOX15NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway REATA PHARMACEUTICALS, INC (US) 2023-11-28 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ICMT 2894/4885CHRM3 298/4885MAPT 3986/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ICMT 2894/4885CHRM3 298/4885MAPT 3986/4885
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway HSPA2, HSP90AB2P, HSF1 ICMT 3978/4885CHRM3 4453/4885MAPT 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.